nursing home or extended care facility (nursing homeacquired pneumonia, or NHAP), receipt of home infusion therapy (including antibiotics), chronic dialysis within 30 days, home wound care, and exposure to a family member infected with a MDR pathogen. Other studies [2] of HCAP have included patients with immune compromise, but this group was excluded from the ATS/IDSA definition. One potentially at-risk population that was not mentioned is the healthcare worker, especially those with chronic medical illnesses who care for patients infected with MDR pathogens.
The ATS/IDSA guideline stated that all patients with HCAP should receive empiric therapy directed at MDR pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. This means that all HCAP patients would require parenteral therapy with usually three different antibiotics. The recommendation was based on a limited number of studies available at the time, primarily from the USA, but since then, other studies from other countries, as well as the USA, have reported a different picture of HCAP, with a lower frequency of MDR pathogens calling into question the need for routine broad-spectrum empiric therapy [2] [3] [4] [5] [6] [7] [8] . In addition, in North America, it is clear that not all HCAP patients are severely ill or even hospitalized when they develop pneumonia, and these patients, generally residing in nursing homes, can receive oral antibiotic therapy with single agents with great success, somewhat contrary to the recommendations of the guideline [9] .
The purpose of this review is to examine the current data published after the literature review used for the guidelines to better understand the population of patients with HCAP, their associated bacteriology, therapy, and the success of therapy, in order to recommend an updated approach for antibiotic management.
Search strategy
Studies of HCAP therapy were evaluated by searching PubMed in September 2008. Initially, when the term HCAP (614 studies) was combined with the term antibiotic therapy (234 208 studies), using the word 'and', a total of 160 studies remained. When the term nursing home pneumonia was combined with the term antibiotic therapy, there were 168 studies. These searches were limited to adults, clinical trials, reviews, meta-analyses, or practice guidelines. To broaden the search, the term hemodialysis was combined with the term pneumonia to yield 403 studies, and when the term hemodialysis was combined with the term pneumonia bacteriology, there were 70 studies.
This database of studies was reviewed and cross-referenced to identify original studies of therapy or bacteriology of patient populations, or both, included within the definition of HCAP.
Inclusion/exclusion criteria
As a background, the recovered studies were reviewed to provide perspective on the problem of HCAP bacteriology and therapy. However, only studies published since July 2004 were included in the detailed analysis in order to update the database that was used to develop the 2005 ATS/IDSA guidelines. Included studies were retrospective or prospective observational cohorts of patients included within the category of HCAP. Prospective studies of therapy were also included, but none enrolled a mixed HCAP population, and all only involved nursing home patients. Although some studies included immunesuppressed populations, any study dealing exclusively with immune-suppressed patients was excluded. Abstracts, not published in full, were not considered.
Data extraction and synthesis
Studies were examined to define the bacteriology of HCAP, site of care, therapy used, and the relationship of outcome to therapy. The search strategy yielded six studies [2] [3] [4] [5] 7, 10] of HCAP that included more than just nursing home patients, three were retrospective and observational with no randomized intervention, and two of these three involved the same patients. Two studies [5, 7] were prospective observational reports, one comparing HCAP with community-acquired pneumonia (CAP) and one comparing NHAP with nosocomial pneumonia. Another study used case-control methodology, but whereas the latter included HCAP with other healthcare-associated infections, it only examined patients infected with MRSA [10] . Studies were from North America (three studies), Europe (two studies), and Japan (one study). Two of the North American studies [2, 4] involved the same population, but each study evaluated different aspects of bacteriology and therapy. We also evaluated four other studies [6, 8, 11, 12] in which the only HCAP patients evaluated were those with NHAP, but all of these were prospective and observational, two from Europe and two from the USA. The studies from the USA [11, 12] were the only ones to systematically use quantitative bronchoscopic culture sampling, and there was some overlap in the included population of patients.
We combined the eight unique HCAP study populations that were evaluated either prospectively or retrospectively and that had bacteriologic data on both Grampositive and Gram-negative bacteria into Tables 1  and 2 [2, 3, [5] [6] [7] [8] 11, 12] . Study size varied, with the North American studies having 75 and 135 and 431 and 988 HCAP patients, whereas the European studies had population sizes of 25, 126, and 205 HCAP patients, and the Japanese study had 75 HCAP patients. An additional retrospective study [13] was included, but it only focused on patients with pneumonia and hemodialysis and provided limited bacteriologic data with no comment on therapy.
Three additional prospective therapy trials were also evaluated, but only involved HCAP patients who came from nursing homes (NHAP). In one study [9] , 680 patients were evaluated, some treated in the hospital with intravenous or oral therapy, whereas others received oral therapy in the nursing home. In one of the other studies, 69 patients were treated parenterally in the nursing home, whereas in the other study, 51 were treated intravenously in the hospital [14, 15] . Another study [16] was reviewed but not analyzed in detail, because even though it examined 170 nursing home pneumonia patients admitted to the hospital, it provided very limited data about bacteriology and the specific antibiotic therapy used.
Results
The studies included in Tables 1 and 2 incorporated a heterogeneous group of patients, with a wide range of bacteriology. In general, the studies that included mainly patients who had recently been hospitalized or those with severe NHAP had a higher frequency of MDR pathogens than the studies that included HCAP patients who were less severely ill or who met this definition for reasons other than recent hospitalization. These findings are consistent with an algorithm presented in one of the NHAP studies by El Solh et al. [11] . In that study [11] , there were 88 patients with severe NHAP, but only 17 had drug-resistant pathogens, and they were individuals who, in addition to severe illness, had either a history of antibiotic therapy for at least 3 days in the past 6 months, a poor functional status (defined by activities of daily living), or both.
Micek et al. [2] retrospectively studied the bacteriology of HCAP and CAP in 639 patients at a single US hospital over a 3-year period (2003) (2004) (2005) . Unlike some other HCAP studies, all pneumonia patients had positive bacteriology, with cultures collected from sputum, tracheal aspirate, bronchoscopy samples, or blood cultures. HCAP was defined similar to the ATS/IDSA guidelines with the exception that the investigators also included those hospitalized in the past 12 months (rather than 3 months) and also those with immune suppression (steroid therapy of at least 5 mg prednisone/day, HIV Healthcare-associated pneumonia: special commentary Brito and Niederman 319 The findings by Micek et al. [2] differ from the data of Carratala et al. [5] , a Spanish study which compared 126 HCAP patients with 601 CAP patients. Although they showed a higher frequency of inappropriate therapy and mortality in HCAP than in CAP patients, the mortality was much lower than in the study by Micek et al. [2] , and there was also a much lower frequency of MDR pathogens in HCAP patients than was found in the study by Micek et al. [2] . In the study, both MRSA and enteric Gram negatives were more common in HCAP than in CAP patients, but in the HCAP patients, the frequency of S. aureus was only 2.4%, and the frequency of enteric Gram negatives was only 4%. The therapy used for these patients reflected the bacteriology. Overall, 75% received monotherapy, 62% with a b-lactam and 10% with a quinolone. When a combination regimen was used, it consisted of a b-lactam and quinolone in 21% and b-lactam and a macrolide in 3%. Thus, many patients did receive a CAP regimen, but the frequency of inappropriate therapy was only 5.6%.
The disparate findings between these two studies may be related to differences in study design and in the population enrolled ( The Japanese study [7] prospectively compared 75 patients with NHAP with 33 patients with HAP. The study was done in a rural area that has over 30% of the population above the age of 65 years. All the patients with NHAP had been institutionalized for at least 5 days prior to the onset of pneumonia. Immune-suppressed and dialysis patients were excluded from this study. Only 8.5% of the NHAP patients were admitted to the ICU. The mortality rate of NHAP was high at 37.3%, but still lower than for HAP. In spite of this high mortality, there was a relatively low frequency of MDR pathogens, with only 4% having S. aureus and 5.3% having enteric Gram negatives. In the study, 72% of the NHAP patients had an etiologic diagnosis, and the surprising finding in this study was the high frequency of atypical pathogens, which were found in 37.3% of the NHAP population, primarily Chlamydophila pneumoniae, diagnosed serologically. The high frequency of atypical pathogens contrasts with the other studies of HCAP, but this was the only study to systematically look for evidence of their presence. Only about half of the NHAP patients received a macrolide or minocycline, and although those with Chlamydophila who were appropriately treated had a 71% response rate, mortality was not affected by this appropriate initial therapy, raising a question about the importance of this organism. The therapy of NHAP was more often dual therapy than in the HAP population, but the HAP patients tended to receive broader spectrum drugs with more carbapenem and less cephalosporin use than the HCAP patients.
The other HCAP studies were not as well detailed or did not include as heterogeneous a population. Kollef et al. [3] retrospectively analyzed a large database of 4543 pneumonia patients of whom 988 had HCAP. In this population, 49.6% of patients with HCAP came from a nursing home, and 24.1% were mechanically ventilated, but there is no mention of the percentage who were admitted to the ICU [3] . The mortality of HCAP was similar to that of nosocomial pneumonia, higher than that of CAP, and lower than ventilatorassociated pneumonia. The most common organism in the HCAP population was S. aureus, present in 46.7% (57% of these were MRSA), and P. aeruginosa (25.3%). This study is limited by its retrospective dependence on a database with bacteriologic data of uncertain accuracy. The French study [10] was a prospective case-control evaluation of the risk factors for healthcare-associated MRSA infections that were diagnosed within 48 h of admission. Of the 175 MRSA cases, only 41 were pneumonia, and patients and the HCAP risk factors were defined for the entire group, not just the pneumonia patients. These risks were: hospitalization within the past 3 years (85%), home nursing care within the past 3 years (65%), transfer from another healthcare facility (25%), family contact with the healthcare environment (52%), and antibiotic use in the past 6 months (53%). This study is obviously limited by its study of only MRSA, but it did identify risk factors for healthcare-associated MRSA infection that were: prior receipt of home nursing care (which showed an exposure-frequency relationship), prior hospitalization, transfer from another institution, and age of more than 65 years.
The four studies of NHAP give additional data about bacteriology, but are limited by the populations studied and the data provided. The Spanish study [6] evaluated only 25 hospitalized patients with NHAP, and only six had an etiologic diagnosis, which was mostly based on blood cultures. Although none were admitted to the ICU, 28% died, and the identified organisms were: S. pneumoniae in two, S. aureus in three, and enteric Gram negatives in one. The specific therapies used were not specified, but initial therapy was changed in 16% of the patients with NHAP. El Solh et al. [11, 12] did two studies of NHAP patients, all with severe illness requiring mechanical ventilation and admitted to the ICU. In the first study [11] , 135 patients were evaluated, 88 to derive a prediction rule for bacteriology and 47 to validate the rule. The study excluded patients who had been hospitalized in the past 6 months and those with immune suppression. Of the 135 patients, 93 had a microbial cause defined by extensive diagnostic testing, including protected bronchoalveolar lavage (PBAL). The organisms found were: S. aureus in 31% (20% of all patients had MRSA), enteric Gram negatives in 28% (9% of all patients had P. aeruginosa), and S. pneumoniae in 25%. The authors derived and validated a prediction model for the presence of MDR pathogens. All patients had severe pneumonia, but MDR pathogens were absent from those with no history of prior antibiotics and with good functional status (based on activities of daily living score). The frequency of MDR pathogens was highest in those with both risk factors, and those who received prior antibiotics as the only risk factor had a higher frequency of MDR pathogens than those with poor functional status as the only risk factor. For the 135 patients, the sensitivity of the model for predicting MDR pathogens was 100%, with a specificity of 58.9%. No therapy information was given in this study.
The second study by El Solh et al. [12] did report extensive microbiology on 75 patients with NHAP (excluding those with immune suppression), all of whom were mechanically ventilated, but no details of therapy or outcome were provided. However, this study is the only one to systematically use quantitative bronchoscopic cultures, both protected specimen brush (PSB) and BAL. They found organisms present above a quantitative threshold in 49 of the patients, with 56 different microorganisms. S. aureus was most common (n ¼ 13), followed by S. pneumoniae (n ¼ 7) and Escherichia coli (n ¼ 7). Although other Gram negatives were identified (Serratia marcescens and Proteus mirabilis), only three bronchoscopic samples showed P. aeruginosa, and Acinetobacter was not reported. Interestingly, the authors found that in this intubated population, quantitative endotracheal aspirates correlated well with the results from quantitative bronchoscopy.
The other study [8] to include NHAP was a prospective study of 2647 CAP patients that compared older patients with younger individuals, but did include within the study 205 individuals coming from nursing homes who would now be classified as having HCAP. Compared with CAP patients, those with NHAP had a higher incidence of Gram negatives (18.8%), but the incidence of S. aureus (2.3%) and P. aeruginosa (1%) was relatively low. The presence of NHAP increased mortality by four-fold compared with elderly CAP patients living in the community. Specific therapy was not described, but 39.7% had some change in antibiotics, with 14% having a change due to ineffectiveness and 2% due to resistance. In contrast to some of the other studies, the investigators excluded any NHAP patient with a recent hospitalization (within 28 days).
Hemodialysis patients are also included within the HCAP definition, but there are few studies of pneumonia in this population. One study [13] retrospectively analyzed a Medicare database of 10 635 dialysis patients and provided limited data about pneumonia bacteriology. In the study, of the 3101 pneumonia hospitalizations, no cause was identified in 82%. When an organism was found, Gram negatives outnumbered Gram positives almost two to one (11.1 versus 4.8% of all). No comments were made about therapy. In this group, staphylococcal species were present in 0.4% and P. aeruginosa in 2.8% of the entire population (recognizing that no pathogen was reported in over 80% of the patients).
There were three prospective, randomized trials of therapy for NHAP that give some insight into the types of therapy that are effective for different subpopulations of patients. One study [9] from Canada included 680 patients who were randomized to usual care or a clinical pathway that attempted to administer oral quinolone therapy and keep the patient from going to the hospital, if possible. Only 110 of the 680 patients were ever hospitalized, making this a less severely ill population than the other studies. There were no bacteriologic data from this study, but the majority of patients were successfully treated with levofloxacin, usually orally, with good outcomes implying the lack of MDR pathogens in most patients. The other therapy studies were prospective randomized, comparative evaluations of two different therapies for NHAP.
One was a prospective, double-blind, randomized study of 74 hospitalized patients with HCAP, with 33 receiving intravenous monotherapy with ertapenem compared with 41 receiving intravenous therapy with cefepime, but patients with pseudomonal risk or severe illness (none were intubated) were excluded [15] . Both monotherapies were highly effective for patients with NHAP, being 90% with cefepime and 75% with ertapenem. These results occurred even though there were many patients with potentially MDR pathogens, although the study also included patients with traditional nosocomial pneumonia, and the bacteriologic data were not separated from those with NHAP. However, among all patients, an etiologic pathogen was found in 53.5%, with the enterobacteriacea in 19.5%, S. pneumoniae in 12.9%, S. aureus in 11.6%, P. aeruginosa in 3.6%, and less than 1% had Acinetobacter infection. The other study [14] randomized 61 patients with NHAP, not requiring hospitalization, to intramuscular therapy, once daily, with either cefepime or ceftriaxone. Only six patients had microbiologic data, but both monotherapies led to similar rates of clinical success: 78% with cefepime and 66% with ceftriaxone. Although these studies indicate that therapies not directed at MDR pathogens were effective for patients with NHAP, one study of a mixed HCAP population showed that MDR pathogens can be present, and if so, they are often treated inappropriately [4] . However, in this study, over 90% of the patients were defined as having HCAP because of recent hospitalization.
Discussion
Many issues enter into the decision about initial empiric therapy of HCAP, and the patients with HCAP are quite heterogeneous with differences in severity of illness (mechanically ventilated or not), site of care (in or out of the hospital), route of therapy (oral, intravenous, or intramuscular), and the underlying reason for being defined as having HCAP. These differences in study design are summarized in Table 2 . In addition, some HCAP patients, particularly those in nursing homes, are at risk for infection with community-based pathogens such as Legionella, C. pneumoniae, and influenza virus. Because of these factors, some patients are at risk for pneumonia with MDR pathogens, whereas others are not, and this can explain why some have been effectively treated with antibiotic regimens that do not target these organisms, whereas others have received a multidrug regimen. For all of these reasons, not all patients with HCAP routinely need the same broad-spectrum antibiotic regimen as patients with complex nosocomial pneumonia, as suggested in the ATS/IDSA HAP guidelines [1] . When the ATS/IDSA guidelines suggested that HCAP should be treated similar to HAP, with a focus on MDR pathogens, the implied, but not stated, assumption was that the patients being evaluated were those in the hospital who would be treated with intravenous antibiotics, and this assumption did not account for the heterogeneity of HCAP populations. We believe that the proper approach to empiric therapy of HCAP is complex, necessitating the definition of subpopulations, some of which should be managed similar to nosocomial pneumonia, some similar to CAP, and some with a hybrid approach, both in the choice of therapeutic agents as well as in the site of care and route of antibiotic administration.
The data reviewed not only highlight the complexity of HCAP, but also demonstrate that for many patients, the routine use of a broad-spectrum, multidrug regimen is unnecessary and may lead to overuse of antibiotics. Not only do many patients not have infection with MDR pathogens, but studies in the past, as well as recently, have demonstrated the efficacy of CAP regimens and of monotherapy with agents that would not be recommended for HAP patients at risk for MDR pathogens such as levofloxacin, cefepime, and ertapenem [9, 14, 15] . In addition, HAP therapy would not adequately treat some HCAP patients who are infected with atypical pathogens such as Legionella and Chlamydophila. Finally, the inclusion of outpatients in the HCAP definition requires that some patients get oral therapy in contrast to intravenous therapy for HAP patients who are already in the hospital.
On the basis of the available information, we propose an algorithm for antibiotic therapy of HCAP that divides patients into four groups based on an assessment of severity of illness (need for mechanical ventilation or ICU admission) and the presence of risk factors for MDR pathogens (Fig. 1) . The risk factors associated with a high frequency of MDR pathogens in the HCAP studies, in addition to severe illness, include: immune suppression, recent hospitalization (within the past 3 months), antibiotic therapy (within the past 6 months), and poor functional status [2, 11] . In addition to these risk factors, it is important to consider local patterns of microbiology, as each hospital setting and nursing home has unique bacteriology, and therapy choices must be modified with such local data in mind [17] .
Patients with nonsevere illness include those with zero to one risk factor, and they can receive CAP therapy, often orally, as an outpatient, with either a quinolone (levofloxacain or moxifloxacin) or a b-lactam (cefuroxime orally or ceftriaxone, cefotaxime, or ertapenem intravenously) in combination with a macrolide. The nonsevere illness group also includes patients with at least two risk factors who should be considered for hospitalization to receive intravenous therapy directed at MDR pathogens, with a two or three-drug HAP regimen. For this latter group, this could be achieved with an antipseudomonal b-lactam (cefepime, imipenem, meropenem, and piperacillin/tazobactam) with an antipseudomonal quinolone (ciprofloxacin or high-dose levofloxacin) or aminoglycoside, with the addition of either linezolid or vancomycin if there is concern about MRSA. If a quinolone is not used (because of allergy, intolerance, or recent therapy in the past 3 months), then addition of a macrolide should be considered, along with the other agents, to provide atypical pathogen coverage.
Patients with severe illness include those with no other additional risk factors for MDR pathogens who should be treated intravenously, generally in the hospital, with dual therapy involving a b-lactam (cefotaxime, ceftriaxone, or ertapenem) with a macrolide or quinolone (levofloxacin or moxifloxacin). Patients with severe illness and at least one other risk factor for MDR pathogens This proposed algorithm, which needs validation, suggests that all patients with HCAP should be identified and then divided on the basis of severity of illness to guide initial therapy. Patients in each group are then further divided based on whether they have risk factors for drug-resistant pathogens (MDR pathogens) that include recent antibiotic therapy in the past 6 months, recent hospitalization in the past 3 months, the presence of immune suppression, and poor functional status as defined by activities of daily living. CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; HCAP, healthcare-associated pneumonia; MDR, multidrug resistant.
should receive intravenous therapy with a three-drug regimen targeting drug-resistant Gram negatives and MRSA, similar to patients with complex nosocomial pneumonia and ventilator-associated pneumonia. This means using an antipseudomonal b-lactam with either an antipseudomonal quinolone or an aminoglycoside, as well as coverage for MRSA with either vancomycin or linezolid.
One limitation of the proposed algorithm is that each risk factor for resistance is weighted similarly. However, a recent publication, using the data set from the study by Micek et al. [2] , suggested that the presence of multiple HCAP risk factors might relate to the frequency of MDR pathogens, but that not all risk factors are equivalent. In that study, 639 patients with pneumonia (including CAP and HCAP) were evaluated, and risk factors for drug-resistant organisms were studied in all patients (not just the 431 with HCAP) [18] . The presence of HCAP did not, by itself, predict the presence of MDR pathogens, and not all HCAP risk factors were equivalent at predicting this risk. In fact, the predictors of resistance were given different point scores, with four for recent hospitalization, three for history of nursing home residence, two for hemodialysis, and one for admission to the ICU. The frequency of MDR pathogens was less than 20% for those with less than three points, 55% for those with three to five points, and 75% for those with more than five points. Prior hospitalization was identified as the most important risk factor for MDR pathogens, but 93.3% of all the HCAP patients in this study (and by definition, none of the CAP patients) had recently been hospitalized, so the discriminating value of this risk may have been overly exaggerated.
Conclusion
HCAP is a heterogeneous disease that includes populations of patients with varying severity of illness and reasons for having had contact with the healthcare environment. Different populations are at different risk for infection with MDR pathogens, and not all patients need a broad-spectrum, multidrug regimen, similar to complex nosocomial pneumonia. An algorithm for therapy that accounts for different subpopulations of HCAP patients is proposed here, and if followed could potentially lead to patients receiving appropriate therapy without the overuse of antibiotics.
These therapy recommendations are based on the best available data, which are quite limited, and future validation of this approach is required. In order for this approach to be validated, patients with a wide range of risk factors and comorbidities must be enrolled and bacteriologic data collected, with the bacteriologic findings being correlated to the risk factors. It may be necessary and possible to weight each of the risk factors for drug-resistant pathogens differently, as demonstrated in the one study [18] mentioned above. Validation studies of algorithms for HCAP therapy will be difficult, as demonstrated by the heterogeneous populations that have been studied to date (Table 2) . Future studies will need to be better organized and should include individuals with all forms of HCAP, not just those with NHAP, and will need to include outpatients as well as inpatients and those admitted to both the hospital ward and the ICU. Patients with immune suppression should be included, as should those with recent hospitalization, but this definition should probably be restricted to those hospitalized in the past 30-90 days and not beyond that time frame. Studies will also need to include patients with and without a specific bacteriologic diagnosis. When studies are restricted to those with an established etiologic diagnosis, they tend to include sicker individuals, many of whom are intubated and mechanically ventilated. In order to study those without a bacteriologic diagnosis, the success of certain therapies should be related to the presence of risk factors for MDR pathogens. As new therapeutic options become available, they too should be specifically tested in HCAP patients, so that data from HAP do not need to be extrapolated to this population.
